Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Dr Reddy’s Laboratories ( (RDY) ) is now available.
Dr. Reddy’s Laboratories has announced the sale of its wholly owned subsidiary, Dr. Reddy’s Laboratories Louisiana LLC, along with its manufacturing facility in Shreveport, Louisiana, USA, to Jaguar Labs Holdings, LLC. This facility is deemed non-strategic, contributing a minimal percentage to the company’s consolidated income and net worth. The transaction is not considered a related party transaction and is expected to be completed by March 18, 2025.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a prominent pharmaceutical company based in India, primarily engaged in the production and distribution of generic medicines and active pharmaceutical ingredients. It focuses on providing affordable and innovative medicines to a wide range of markets globally.
YTD Price Performance: 0.0%
Average Trading Volume: 1,207,457
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $13.13B
For a thorough assessment of RDY stock, go to TipRanks’ Stock Analysis page.
